CurveBeam AI Surges 37% as Investor Optimism Builds
CurveBeam AI (ASX: CVB) caught the market’s attention this week after its share price surged 37 percent in a single move. For a relatively small medical imaging and artificial intelligence company, that kind of rally does not happen without sparking questions. The immediate trigger was an Appendix…
NVIDIA’s $4 Trillion Question: Growth Story or Peak Hype?
NVIDIA (NASDAQ: NVDA) has become one of the most extraordinary success stories in modern markets, climbing to a market value of more than 4 trillion dollars under the leadership of CEO Jensen Huang. Once known primarily for making chips that powered smooth graphics in video games,…
Objective Hits Record Highs as Recurring Revenue Powers Growth
Objective Corporation (ASX:OCL) gave investors plenty to celebrate after its 2025 full-year results sent the stock up 19 percent to fresh all-time highs. For patient shareholders, the rally capped an impressive 80 percent return over the past year. The company has been steadily reshaping itself into…
Megaport’s Strong Results Met With a Sharp Sell-Off
Megaport (ASX:MP1) caught investors off guard this reporting season. Despite delivering strong results, its share price slid 18 percent in a single session. For a company riding the artificial intelligence boom and positioning itself as a leader in Network as a Service, that kind of drop was…
Telix Pharmaceuticals: Controversy, Growth, and the Road Ahead
Every investor knows the uneasy feeling of watching a stock fall, not because of poor earnings, but because of controversy. That is the position Telix Pharmaceuticals (ASX: TLX) finds itself in today. After headlines about an FDA subpoena related to how it communicated drug progress to investors,…
Argent BioPharma Expands with AusCann Deal
On August 19, Argent BioPharma (ASX: RGT) announced it was buying AusCann’s assets, which include the 100% ownership of the Neuvis drug delivery platform, 48% of CannPal Animal Therapeutics, and part of 20% of ECC Pharm.
This deal gives Argent new technology, more research data, and access to the…
Rarely does a stock surge 181% overnight on the back of old drill samples.
That’s exactly what happened when Magnetite Mines (ASX: MGT) jolted the ASX with news of rare earths mineralisation at its Ironback Hill Project in South Australia. For years, this ground was known mainly for iron ore. But by re-testing archived drilling…
Nvidia Q2 Preview: Can the AI Leader Keep Beating Expectations?
For the past two years, Nvidia (NSDQ: NVDA) has delivered quarter after quarter of revenue and earnings beats, yet analysts remain convinced there is still more to come. Ahead of the upcoming Q2 results, investment banks including Morgan Stanley, Cantor Fitzgerald, and Mizuho have all…
CSL’s Growth Slows, Profits Surge: What Investors Need to Know
For decades, CSL Limited (ASX: CSL) has been regarded as one of Australia’s most dependable healthcare giants, the kind of stock you could tuck away and forget. Yet in recent years, even this blue-chip defensive stock has shown it is not immune to market turbulence.…
Dateline Resources (ASX: DTR) Holds 1M+ Oz Gold and Possible REE Upside
It is not often you find a project sitting on over a million ounces of gold in the ground and potentially rare earth elements right next door to one of the world’s largest REE mines.
The Colosseum Gold–REE Project 100% owned by Dateline…
